No company would purposely not disclose a value if it's beneficial to them. This is just common sense and anyone with experience in biotech understands that.
They haven't said that ADL means is not stat sig...have they?
If the ADL means was stat sig (which I don't believe) and AVXL did not disclose that primary endpoint as being met, the company's gross incompetence resulted in an unnecessary 50% loss in enterprise value due to the Street's conclusion that the ADL endpoint was not met.